Study protocol: Minimum effective low dose: anti-human thymocyte globulin (MELD-ATG): phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes

Study protocol: Minimum effective low dose: anti-human thymocyte globulin (MELD-ATG): phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes

Introduction Type 1 diabetes (T1D) is a chronic autoimmune disease, characterised by progressive destruction of the insulin-producing β cells of the pancreas. One immunosuppressive agent that has recently shown promise in the treatment of new-onset T1D subjects aged 12–45 years is antithymocyte glob...

Full description

Saved in:
Bibliographic Details
Main Authors: Simon Bond, David Dunger, Mark Wilson, Adrian Mander, Mikael Knip, Anita Chhabra, M Loredana Marcovecchio, Charlotte S Wilhelm-Benartzi, Michael J Haller, Timothy Tree, Hilde Morobé, Sarah E Miller, Sylvaine Bruggraber, Diane Picton, Katrina Gatley, A Emile J Hendriks, Bärbel Aschemeier-Fuchs, Lut Overbergh, Jaivier Pall, Olivier Arnaud, Almut Nitsche, Anke M Schulte
Format: Article
Language:English
Published: BMJ Publishing Group 2021-12-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/11/12/e053669.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items